REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and…Read More
Ashvattha Therapeutics Announces Appointment of Dr Sakura Minami as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations
